{
  "ticker": "LGP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970107",
  "id": "02970107",
  "pages": 16,
  "price_sensitive": true,
  "date": "20250717",
  "time": "0928",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lwb9gvq8p9j2.pdf",
  "summary": "### **Key Material Information from Little Green Pharma Quarterly Report & Appendix 4C (June 2025)**  \n\n#### **Financial Highlights**  \n- **Revenue**: $9.1M (unaudited, +20% YoY); **Cash receipts**: $12.0M (+50% YoY).  \n- **Cash balance**: $2.5M (up from $2.4M prior quarter); **Unused financing facilities**: >$5.0M.  \n- **FY25 Results (audited)**: Revenue $36.8M (52% CAGR FY22\u2013FY25), NPAT $3.3M, NTA $0.24/share.  \n\n#### **Operational Highlights**  \n- **European growth**: Danish facility sales to Germany +70%; German imports hit record 37.2 tonnes.  \n- **Capacity expansion**: Danish facility now 8.5tpa (+2.4tpa commissioned, another 2.4tpa in progress).  \n- **Regulatory tailwinds**: Danish site approved as EU import/distribution hub effective 1 Jan 2026.  \n\n#### **Market & Product Updates**  \n- **Germany**: Launched branded *CherryCo* flower; adult-use legislation under review (decision late CY25).  \n- **UK**: $2.0M+ purchase orders received for FY26Q2\u2013Q3; market growing rapidly (~60K patients).  \n- **Product mix**: Australian budget flower sales declined (-35%) due to competition; European flower sales surged.  \n\n#### **Liquidity & Capital Structure**  \n- **Net operating cash inflow**: $0.5M (vs. $0.75M outflow prior quarter).  \n- **Debt**: $3.0M long-term; **Enterprise value**: 0.8x revenue, 0.4x NTA.  \n\n**No material capital raising, trading halt, or valuation-impacting announcements identified.**",
  "usage": {
    "prompt_tokens": 5646,
    "completion_tokens": 406,
    "total_tokens": 6052,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T23:38:07.077795"
}